3P Sense Limited 10062547 false 2023-04-01 2024-03-31 2024-03-31 The principal activity of the company is the production and sale of a prototype medical device. Digita Accounts Production Advanced 6.30.9574.0 true true 10062547 2023-04-01 2024-03-31 10062547 2024-03-31 10062547 core:RetainedEarningsAccumulatedLosses 2024-03-31 10062547 core:ShareCapital 2024-03-31 10062547 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 10062547 core:PatentsTrademarksLicencesConcessionsSimilar 2024-03-31 10062547 bus:SmallEntities 2023-04-01 2024-03-31 10062547 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 10062547 bus:FilletedAccounts 2023-04-01 2024-03-31 10062547 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 10062547 bus:RegisteredOffice 2023-04-01 2024-03-31 10062547 bus:Director2 2023-04-01 2024-03-31 10062547 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 10062547 core:PatentsTrademarksLicencesConcessionsSimilar 2023-04-01 2024-03-31 10062547 countries:EnglandWales 2023-04-01 2024-03-31 10062547 2023-03-31 10062547 core:PatentsTrademarksLicencesConcessionsSimilar 2023-03-31 10062547 2022-04-01 2023-03-31 10062547 2023-03-31 10062547 core:RetainedEarningsAccumulatedLosses 2023-03-31 10062547 core:ShareCapital 2023-03-31 10062547 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 10062547 core:PatentsTrademarksLicencesConcessionsSimilar 2023-03-31 iso4217:GBP xbrli:pure

Registration number: 10062547

3P Sense Limited

Unaudited Financial Statements

for the Year Ended 31 March 2024

Brebners
Chartered Accountants
130 Shaftesbury Avenue
London
W1D 5AR

 

3P Sense Limited

Contents

Company Information

1

Statement of Financial Position

2

Notes to the Unaudited Financial Statements

3 to 6

 

3P Sense Limited

Company Information

Director

J W Ndieyira

Registered office

130 Shaftesbury Avenue
2nd Floor
London
W1D 5EU

Accountants

Brebners
Chartered Accountants
130 Shaftesbury Avenue
London
W1D 5AR

 

3P Sense Limited

Statement of Financial Position as at 31 March 2024

Note

2024
£

2023
£

Fixed assets

 

Intangible assets

4

46,672

49,658

Current assets

 

Debtors

5

1,337

1,704

Cash at bank and in hand

 

587

14,954

 

1,924

16,658

Creditors: Amounts falling due within one year

6

(188,756)

(197,951)

Net current liabilities

 

(186,832)

(181,293)

Net liabilities

 

(140,160)

(131,635)

Capital and reserves

 

Called up share capital

100

100

Profit and loss account

(140,260)

(131,735)

Total equity

 

(140,160)

(131,635)

For the financial year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Statement of Income and Retained Earnings has been taken.

Approved and authorised by the director on 27 March 2025
 

.........................................

J W Ndieyira

Director

Company registration number: 10062547

 

3P Sense Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
130 Shaftesbury Avenue
2nd Floor
London
W1D 5EU

The principal activity of the company is the production and sale of a prototype medical device.

2

Accounting policies

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except any items disclosed in the accounting policies as being shown at fair value and are presented in sterling, which is the functional currency of the entity.

Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Going concern

The company made a loss for the year ended 31 March 2024 and had a deficiency of net assets at that date of £140,160.

The company continues to develop a prototype medical device and the company's affairs are simplistic with expenses controllable. COVID-19 delayed matters but the director believes that the company will be able to commence sales within the next few years.

The company funds their working capital requirements through supplier credit and loans from former shareholders. No matters have been drawn to the attention of the director to suggest that this funding will not continue on acceptable terms in the future and the director believes that the company is well placed to manage its business risks successfully.

On the basis of the above, and after making enquiries, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the director continues to adopt the going concern basis in preparing the financial statements.

 

3P Sense Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Research and development

Research and development expenditure is written off in the period in which it is incurred.

Tax

The tax expense for the period comprises deferred tax. Tax is recognised in profit or loss, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Intangible assets

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Trademarks, patents and licences

Straight line over the active term of the agreement

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

3P Sense Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company during the year, was 0 (2023 - 0).

4

Intangible assets

Trademarks, patents and licences
£

Total
£

Cost or valuation

At 1 April 2023

87,942

87,942

Additions

948

948

Disposals

(445)

(445)

At 31 March 2024

88,445

88,445

Amortisation

At 1 April 2023

38,284

38,284

Amortisation charge

3,578

3,578

Amortisation eliminated on disposals

(89)

(89)

At 31 March 2024

41,773

41,773

Carrying amount

At 31 March 2024

46,672

46,672

At 31 March 2023

49,658

49,658

The director believes that there has been no impairment in the carrying value of intangible assets.

 

3P Sense Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

5

Debtors

2024
£

2023
£

Other debtors

1,337

1,704

1,337

1,704

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Trade creditors

2,612

21,037

Other creditors

186,144

176,914

188,756

197,951